Table 2. Baseline characteristics of patients.
| Characteristics | Two-gene expression ratio selection study | P value | Tissue mRNA validation cohort | P value | Urinary nucleic acid validation cohort | P value | |||
|---|---|---|---|---|---|---|---|---|---|
| BPH | PCa | BPH | PCa | BPH | PCa | ||||
| No. | 5 | 12 | 105 | 129 | 31 | 37 | |||
| Age (yr; range) | 69.60 (66-77) | 70.83 (64-81) | 0.791 | 69.30 (46-85) | 69.50 (48-87) | 0.838 | 69.26 (50-81) | 67.30 (58-75) | 0.189 |
| PSA ± SD (ng/mL) | 2.89 ± 1.81 | 47.52 ± 81.98 | 0.027 | 4.17 ± 7.79 | 100.47 ± 239.65 | < 0.001 | 6.52 ± 13.87 | 20.64 ± 25.73 | < 0.001 |
| No. gleason score (%) | |||||||||
| 6 | 0 (0) | 6 (4.7) | 1 (2.7) | ||||||
| 7 | 6 (50.0) | 46 (35.7) | 10 (27.0) | ||||||
| 8 | 4 (33.3) | 36 (27.9) | 18 (48.6) | ||||||
| 9 | 1 (8.3) | 36 (27.9) | 7 (18.9) | ||||||
| 10 | 1 (8.3) | 5 (3.9) | 1 (2.7) | ||||||
| No. stage (%) | |||||||||
| T1 | 0 (0) | 8 (6.2) | 1 (2.7) | ||||||
| T2 | 7 (58.3) | 48 (37.2) | 28 (75.7) | ||||||
| T3 | 4 (33.3) | 34 (26.4) | 8 (21.6) | ||||||
| T4 | 1 (8.3) | 37 (28.7) | 0 (0) | ||||||
| Unknown | 0 (0) | 2 (1.6) | 0 (0) | ||||||
P values were obtained from the Mann-Whitney U-test. BPH, benign prostatic hyperplasia; PCa, prostate cancer; PSA, prostate specific antigen.